Ambrose Allison sold 485 Upstream Bio shares at $5.49 per share on 2026-09-16, leaving 15,563 shares after the transaction. For investors, the reported sale amounted to about 3.0% of Allison’s prior Upstream Bio share holding, while transaction code S classified it as an open-market sale.
Key Highlights
- Upstream Bio shares changed hands at $5.49 each in Ambrose Allison’s transaction.
- Allison’s reported Upstream Bio balance after the trade was 15,563 shares.
- Transaction code S categorised the activity as an open-market sale dated 16 September 2026.
Ambrose Allison sold 485 shares of Upstream Bio, Inc. (NASDAQ: UPB) at $5.49 per share. The transaction took place on 16 September 2026, and Allison retained 15,563 shares afterward. The reported sale represented about 3.0% of Allison’s prior Upstream Bio share holding.
Sale Compared With Prior Holding
The stated 3.0% figure measures the transaction against Allison’s prior shares holding in Upstream Bio. The reported balance after the transaction remained 15,563 shares.
FAQs
Q: How many Upstream Bio shares did Ambrose Allison sell and at what price?
A: Ambrose Allison sold 485 Upstream Bio shares at $5.49 per share. The transaction was dated 16 September 2026.
Q: What percentage of Ambrose Allison’s prior Upstream Bio holding did the sale represent?
A: The Upstream Bio insider transaction represented about 3.0% of Ambrose Allison’s prior shares holding. Allison held 15,563 shares after the sale.
Q: What does transaction code S mean for Ambrose Allison’s Upstream Bio trade?
A: Code S identifies an open-market sale in insider transaction reporting. The Upstream Bio transaction occurred on 16 September 2026.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.